9. Merck ( MRK) is a global pharmaceutical company. It is scheduled to report fourth-quarter results today.

Merck's stock has been dragged down by pipeline woes over the past year, dropping 15%. However, its dividend yield, at 4.5%, is fourth-highest in the Dow. In addition to being historically cheap, Merck sells at a substantial discount to its peer group. The stock trades at a forward earnings multiple of 9, a book value multiple of 1.9, a sales multiple of 2.4 and a cash flow multiple of 12, 26%, 73%, 30% and 7% discounts to pharma industry averages.

12-Month Sales Growth: 88%
12-Month Profit Growth: -2.1%
12-Month Stock Performance: -15%
3-Year Annualized Sales Growth: 22%
3-Year Annualized Profit Growth: 14%
3-Year Annualized Stock Performance: -10%

Current Dividend Yield: 4.5%
3-Year Annualized Dividend Growth: 0%
5-Year Annualized Dividend Growth: 0%

Bullish Scenario: Credit Suisse rates Merck "outperform", expecting its stock to climb 30% to $44.

Bearish Scenario: Jefferies ranks Merck "hold", predicting that its stock will inch up 2% to $34.50.

If you liked this article you might like

7 Essential Rules for Investing in Tech Stocks

Tax Reform Is Coming and That Means Trump Stock Rally Is Ready to Kill It Again

'Trump Stock' Rally Is Back on Track

These Stocks Pay You to Own Them

Pret A Manger Takeover in the Works; Cisco's M&A Shackles Come Off - ICYMI